Header Logo

Connection

MALCOLM BRENNER to Genetic Markers

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Genetic Markers.
MALCOLM BRENNER
Connection Strength
1.774
Genetic Markers
  1. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
    View in: PubMed
    Score: 0.148
  2. Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
    View in: PubMed
    Score: 0.127
  3. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
    View in: PubMed
    Score: 0.110
  4. Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
    View in: PubMed
    Score: 0.106
  5. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
    View in: PubMed
    Score: 0.105
  6. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
    View in: PubMed
    Score: 0.104
  7. The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
    View in: PubMed
    Score: 0.102
  8. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
    View in: PubMed
    Score: 0.093
  9. Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
    View in: PubMed
    Score: 0.091
  10. Gene marking to improve the outcome of autologous bone marrow transplantation. Prog Clin Biol Res. 1994; 389:587-91.
    View in: PubMed
    Score: 0.091
  11. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
    View in: PubMed
    Score: 0.091
  12. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993 Jan 09; 341(8837):85-6.
    View in: PubMed
    Score: 0.085
  13. The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
    View in: PubMed
    Score: 0.057
  14. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.042
  15. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999 Dec 10; 10(18):3067-123.
    View in: PubMed
    Score: 0.034
  16. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
    View in: PubMed
    Score: 0.031
  17. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
    View in: PubMed
    Score: 0.030
  18. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
    View in: PubMed
    Score: 0.030
  19. Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
    View in: PubMed
    Score: 0.029
  20. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
    View in: PubMed
    Score: 0.028
  21. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
    View in: PubMed
    Score: 0.027
  22. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
    View in: PubMed
    Score: 0.027
  23. The use of cytokines to improve gene transfer to human hematopoietic stem cells. Cytokines Mol Ther. 1995 Mar; 1(1):3-9.
    View in: PubMed
    Score: 0.025
  24. Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep; 23:S56-7.
    View in: PubMed
    Score: 0.024
  25. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
    View in: PubMed
    Score: 0.023
  26. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
    View in: PubMed
    Score: 0.023
  27. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood. 1992 May 15; 79(10):2694-700.
    View in: PubMed
    Score: 0.020
  28. Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther. 1992 Apr; 3(2):129-36.
    View in: PubMed
    Score: 0.020
  29. [Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38.
    View in: PubMed
    Score: 0.011
  30. Human gene marker/therapy clinical protocols. Hum Gene Ther. 2000 Apr 10; 11(6):919-79.
    View in: PubMed
    Score: 0.009
  31. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
    View in: PubMed
    Score: 0.008
  32. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
    View in: PubMed
    Score: 0.008
  33. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
    View in: PubMed
    Score: 0.006
  34. European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
    View in: PubMed
    Score: 0.006
  35. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.